Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. (AVIR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
avir · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Atea Pharmaceuticals, Inc. (AVIR) measures how much investors pay for each dollar of the company's trailing earnings. AVIR's current PE ratio of N/A is calculated by dividing its stock price of $4.32 by its TTM earnings per share of -$2.14.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2018 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Atea Pharmaceuticals, Inc.You AVIR | $346M | N/A | — | -$2.14 |
 Achieve Life Sciences, Inc. ACHV | $563M | N/A | — | -$1.25 |
 Allogene Therapeutics, Inc. ALLO | $451M | N/A | — | -$0.87 |
 Arcturus Therapeutics Holdings Inc. ARCT | $202M | N/A | — | -$2.40 |
 Enanta Pharmaceuticals, Inc. ENTA | $257M | N/A | — | -$3.84 |
 Humacyte, Inc. HUMA | $232M | N/A | — | -$0.26 |
 Pyxis Oncology, Inc. PYXS | $107M | N/A | — | -$1.28 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.94 | — | |
2024-12-31 FY2024 | — | $-2.00 | — | |
2023-12-31 FY2023 | — | $-1.63 | — | |
2022-12-31 FY2022 | — | $-1.39 | — | |
2021-12-31 FY2021 | 6.11x | $1.46 | — | |
2020-12-31 FY2020 | — | $-0.13 | — | |
2019-12-31 FY2019 | — | $-0.16 | — | |
2018-12-31 FY2018 | — | $-0.90 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Atea Pharmaceuticals, Inc. (AVIR) measures how much investors pay for each dollar of the company's trailing earnings. AVIR's current PE ratio of N/A is calculated by dividing its stock price of $4.32 by its TTM earnings per share of -$2.14.
Frequently asked questions
AVIR pe ratio · 6 questionsAVIR's current PE ratio is N/A as of 2026-06-08, based on a stock price of $4.32 and TTM EPS of -$2.14. Data sourced from Financial Modeling Prep via AVIR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Atea Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08